155 related articles for article (PubMed ID: 34666183)
1. Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effect.
Zhang M; Fang Z; Zhang H; Cui M; Wang M; Liu K
Eur J Pharm Sci; 2022 Jan; 168():106044. PubMed ID: 34666183
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional metal complex-based gene delivery for tumour immune checkpoint blockade combination therapy.
Zhang M; Fang Z; Cui M; Liu K
J Drug Target; 2022 Aug; 30(7):753-766. PubMed ID: 35311603
[TBL] [Abstract][Full Text] [Related]
4. Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide.
Tseng JC; Yang JX; Liu YL; Su YW; Lee AY; Chen YW; Liu KJ; Luo Y; Hong YR; Chuang TH
Cancer Immunol Immunother; 2022 May; 71(5):1115-1128. PubMed ID: 34581869
[TBL] [Abstract][Full Text] [Related]
5. Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment.
Zhao H; Zhao B; Wu L; Xiao H; Ding K; Zheng C; Song Q; Sun L; Wang L; Zhang Z
ACS Nano; 2019 Nov; 13(11):12553-12566. PubMed ID: 31689085
[TBL] [Abstract][Full Text] [Related]
6. Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer.
Teranishi S; Kobayashi N; Katakura S; Kamimaki C; Kubo S; Shibata Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2020 Apr; 11(4):983-992. PubMed ID: 32067413
[TBL] [Abstract][Full Text] [Related]
7. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.
Chen B; Gao A; Tu B; Wang Y; Yu X; Wang Y; Xiu Y; Wang B; Wan Y; Huang Y
Biomaterials; 2020 Oct; 255():120187. PubMed ID: 32590192
[TBL] [Abstract][Full Text] [Related]
8. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
9. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence.
Li M; Guo R; Wei J; Deng M; Li J; Tao Y; Li M; He Q
Acta Biomater; 2021 Dec; 136():546-557. PubMed ID: 34536603
[TBL] [Abstract][Full Text] [Related]
10. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
12. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
14. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
15. Sialidase-Conjugated "NanoNiche" for Efficient Immune Checkpoint Blockade Therapy.
Zhou ZR; Wang XY; Jiang L; Li DW; Qian RC
ACS Appl Bio Mater; 2021 Jul; 4(7):5735-5741. PubMed ID: 35006749
[TBL] [Abstract][Full Text] [Related]
16. Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment.
Kwantwi LB
Clin Exp Med; 2023 Nov; 23(7):3077-3091. PubMed ID: 37022584
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
18. A Totipotent "All-In-One" Peptide Sequentially Blocks Immune Checkpoint and Reverses the Immunosuppressive Tumor Microenvironment.
Zhang L; Jiang Z; Yang X; Qian Y; Wang M; Wu S; Li L; Jia F; Wang Z; Hu Z; Zhao M; Tang X; Li G; Shang H; Chen X; Wang W
Adv Mater; 2023 Jan; 35(2):e2207330. PubMed ID: 36259590
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
